Literature DB >> 11170301

Role of TGFbeta signaling in skin carcinogenesis.

X J Wang1.   

Abstract

The TGFbeta signaling pathway is one of the most important mechanisms in the maintenance of epithelial homeostasis. Alterations leading to either the repression or enhancement of this pathway have been shown to affect cancer development. Although TGFbeta inhibits growth of normal epithelial cells, it is paradoxically overexpressed in many epithelial cancers. It has been postulated that TGFbeta acts as a tumor suppressor at the early stages of carcinogenesis, but overexpression of TGFbeta at late stages of carcinogenesis may be a critical factor for tumor invasion and metastasis. The detailed mechanisms regulating this functional switch of TGFbeta remain to be elucidated. The relevance of the TGFbeta signaling pathway to the development of primary epithelial tumors in man has been further substantiated by the discovery of mutations in TGFbeta receptors and in the downstream signaling mediators, the Smads. The epidermis is one of the major targeting tissues for TGFbeta signaling. Chemical carcinogenesis studies have revealed a paradoxical effect of TGFbeta on skin carcinogenesis: inhibition of papilloma formation but promotion of malignant conversion. In addition, deletion of the TGFbeta type II receptor accelerates skin carcinogenesis. This review focuses on our current understanding of the role of TGFbeta signaling in skin carcinogenesis. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11170301     DOI: 10.1002/1097-0029(20010215)52:4<420::AID-JEMT1027>3.0.CO;2-7

Source DB:  PubMed          Journal:  Microsc Res Tech        ISSN: 1059-910X            Impact factor:   2.769


  8 in total

1.  TGF-β1 regulates the invasive and metastatic potential of mucoepidermoid carcinoma cells.

Authors:  Jing Wang; Jian Chen; Kailiang Zhang; Yuan Zhao; Jacques E Nör; Junzheng Wu
Journal:  J Oral Pathol Med       Date:  2011-06-21       Impact factor: 4.253

2.  Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.

Authors:  Gangwen Han; Shi-Long Lu; Allen G Li; Wei He; Christopher L Corless; Molly Kulesz-Martin; Xiao-Jing Wang
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

3.  Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma.

Authors:  Shi-Long Lu; Heather Herrington; Douglas Reh; Stephen Weber; Sophia Bornstein; Donna Wang; Allen G Li; Chin-Fang Tang; Yasmin Siddiqui; Jo Nord; Peter Andersen; Christopher L Corless; Xiao-Jing Wang
Journal:  Genes Dev       Date:  2006-05-15       Impact factor: 11.361

4.  Integrin alpha3beta1 potentiates TGFbeta-mediated induction of MMP-9 in immortalized keratinocytes.

Authors:  John M Lamar; Vandana Iyer; C Michael DiPersio
Journal:  J Invest Dermatol       Date:  2007-08-30       Impact factor: 8.551

5.  Elevating CLIC4 in Multiple Cell Types Reveals a TGF- Dependent Induction of a Dominant Negative Smad7 Splice Variant.

Authors:  Anjali Shukla; Yihan Yang; Sara Madanikia; Yan Ho; Mangmang Li; Vanesa Sanchez; Christophe Cataisson; Jing Huang; Stuart H Yuspa
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

Review 6.  Primary Ciliary Signaling in the Skin-Contribution to Wound Healing and Scarring.

Authors:  Mayu Hosio; Viljar Jaks; Heli Lagus; Jyrki Vuola; Rei Ogawa; Esko Kankuri
Journal:  Front Cell Dev Biol       Date:  2020-11-13

7.  Receptor type protein tyrosine phosphatase-kappa mediates cross-talk between transforming growth factor-beta and epidermal growth factor receptor signaling pathways in human keratinocytes.

Authors:  Yiru Xu; Dustin Baker; TaiHao Quan; Joseph J Baldassare; John J Voorhees; Gary J Fisher
Journal:  Mol Biol Cell       Date:  2009-10-28       Impact factor: 4.138

8.  The FYVE domain of Smad Anchor for Receptor Activation (SARA) is required to prevent skin carcinogenesis, but not in mouse development.

Authors:  Huang-Ming Chang; Yu-Ying Lin; Pei-Chun Tsai; Chung-Tiang Liang; Yu-Ting Yan
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.